Today: The CVS Health Corporation (CVS) Lifted to “Buy” at Vetr Inc.

The CVS Health Corporation (CVS) Lifted to “Buy” at Vetr Inc.

Vetr upgraded shares of CVS Health Corporation (NYSE:CVS) from a hold rating to a buy rating in a research report report published on Monday morning. They currently have $94.49 target price on the pharmacy operator’s stock.

Several other equities research analysts also recently weighed in on CVS. Leerink Swann restated a buy rating on shares of CVS Health Corporation in a report on Wednesday, August 3rd. Zacks Investment Research upgraded CVS Health Corporation from a sell rating to a hold rating in a report on Wednesday, August 3rd. FBR & Co restated an outperform rating and set a $120.00 price target on shares of CVS Health Corporation in a report on Wednesday, August 3rd. Morgan Stanley restated a hold rating and set a $104.00 price target on shares of CVS Health Corporation in a report on Wednesday, August 3rd. Finally, Deutsche Bank AG upped their price target on CVS Health Corporation from $99.00 to $108.00 and gave the stock a hold rating in a report on Wednesday, August 3rd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $112.40.

Shares of CVS Health Corporation (NYSE:CVS) opened at 88.00 on Monday. The company’s 50 day moving average price is $90.25 and its 200-day moving average price is $96.54. The firm has a market cap of $93.83 billion, a P/E ratio of 20.24 and a beta of 0.83. CVS Health Corporation has a 12-month low of $85.41 and a 12-month high of $106.67.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.02. CVS Health Corporation had a return on equity of 15.86% and a net margin of 2.88%. The company had revenue of $43.70 billion for the quarter, compared to the consensus estimate of $44.28 billion. During the same quarter in the prior year, the business earned $1.19 EPS. CVS Health Corporation’s revenue was up 17.6% on a year-over-year basis. On average, equities research analysts anticipate that CVS Health Corporation will post $5.86 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 3rd. Investors of record on Monday, October 24th will be paid a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 1.93%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s payout ratio is currently 39.08%.

A number of institutional investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC increased its position in CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock valued at $102,000 after buying an additional 900 shares during the last quarter. MU Investments Co. Ltd. increased its position in CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock valued at $109,000 after buying an additional 440 shares during the last quarter. Pinkerton Retirement Specialists LLC increased its position in CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock valued at $110,000 after buying an additional 1,112 shares during the last quarter. D Orazio & Associates Inc. increased its position in CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 100 shares during the last quarter. Finally, Cantab Capital Partners LLP increased its position in CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock valued at $113,000 after buying an additional 924 shares during the last quarter. 80.95% of the stock is owned by hedge funds and other institutional investors.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment